prnewswire.com
Positivewww.prnewswire.com ·
photocure asa results for the first quarter of 2026 302765168
TAX_WORLDLANGUAGES_NORWEGIANMANMADE_DISASTER_IMPLIEDTAX_FNCACT_EXECUTIVE_OFFICERECON_WORLDCURRENCIES_DOLLAR
The full article is on the original publisher site. This page only shows the headline and a very short excerpt.
AI insight
AI-generatedPhotocure's revenue growth is driven by Hexvix/Cysview sales and Saphira tower installations. FDA reclassification of blue-light cystoscopy equipment could expand market access. Cevira approval in China and EU marketing application are milestones. Commercial mechanism: regulatory catalyst for medical device adoption, direct revenue impact from product sales. Impact is company-specific and regulatory-driven.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- Photocure Q1 2026 revenues NOK 264.6M, up from NOK 125.3M YoY.
- Hexvix/Cysview sales NOK 139.0M in Q1 2026.
- Adjusted EBITDA NOK 15.3M vs NOK 9.7M prior year.
- 11 new Saphira towers installed in U.S.; active accounts up 21% to 413.
- FDA to initiate reclassification of blue-light cystoscopy equipment in H2 2026.